Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DNA OTCMKTS:PFSCF NASDAQ:TYRA NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$13.38+18.2%$9.11$5.00▼$16.85$662.58M1.481.45 million shs3.62 million shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/ATYRATyra Biosciences$10.29-3.0%$9.89$6.42▼$29.60$563.28M1.07293,047 shs233,324 shsZVRAZevra Therapeutics$11.58-1.3%$9.62$5.45▼$13.16$641.39M1.97741,356 shs720,409 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks+11.60%+14.03%+32.49%+50.23%-15.46%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%TYRATyra Biosciences+2.12%-2.75%+14.95%+12.04%-46.22%ZVRAZevra Therapeutics-2.82%-8.29%+29.76%+60.47%+93.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNAGinkgo Bioworks0.6914 of 5 stars1.01.00.00.02.52.50.6PFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ATYRATyra Biosciences3.1138 of 5 stars3.55.00.00.01.23.30.0ZVRAZevra Therapeutics3.2654 of 5 stars3.65.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNAGinkgo Bioworks 2.00Hold$8.50-36.48% DownsidePFSCFProMetic Life Sciences 0.00N/AN/AN/ATYRATyra Biosciences 3.00Buy$30.83199.64% UpsideZVRAZevra Therapeutics 3.11Buy$23.71104.79% UpsideCurrent Analyst Ratings BreakdownLatest PFSCF, TYRA, DNA, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.007/2/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.007/1/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/21/2025TYRATyra BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$33.005/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNAGinkgo Bioworks$227.04M3.45N/AN/A$13.17 per share1.02PFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08TYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/AZVRAZevra Therapeutics$23.61M26.82N/AN/A$0.74 per share15.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/ATYRATyra Biosciences-$86.48M-$1.630.00N/AN/AN/A-26.90%-25.54%8/6/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$1.900.0057.90N/A-226.78%-201.05%-53.55%8/12/2025 (Estimated)Latest PFSCF, TYRA, DNA, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DNAGinkgo Bioworks-$1.44N/AN/AN/AN/AN/A8/12/2025Q2 2025ZVRAZevra Therapeutics$0.65N/AN/AN/A$22.49 millionN/A8/6/2025Q2 2025TYRATyra Biosciences-$0.53N/AN/AN/AN/AN/A5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNAGinkgo BioworksN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNAGinkgo BioworksN/A4.884.88PFSCFProMetic Life SciencesN/A0.950.71TYRATyra BiosciencesN/A22.7822.78ZVRAZevra Therapeutics1.463.022.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNAGinkgo Bioworks78.63%PFSCFProMetic Life Sciences0.10%TYRATyra Biosciences84.14%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipDNAGinkgo Bioworks9.72%PFSCFProMetic Life SciencesN/ATYRATyra Biosciences15.20%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionablePFSCFProMetic Life Sciences5023.31 millionN/ANot OptionableTYRATyra Biosciences2053.09 million45.02 millionOptionableZVRAZevra Therapeutics2054.68 million53.37 millionOptionablePFSCF, TYRA, DNA, and ZVRA HeadlinesRecent News About These CompaniesAIGH Capital Management LLC Has $10.77 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 22 at 12:21 PM | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to "Buy" at Wall Street ZenJuly 22 at 2:13 AM | americanbankingnews.comZevra Therapeutics (NASDAQ:ZVRA) Downgraded to Buy Rating by Wall Street ZenJuly 20 at 2:50 AM | marketbeat.comZevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)July 18, 2025 | globenewswire.comQ2 EPS Forecast for Zevra Therapeutics Boosted by AnalystJuly 18, 2025 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.July 17, 2025 | marketbeat.comWilliam Blair Issues Optimistic Forecast for ZVRA EarningsJuly 17, 2025 | americanbankingnews.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...July 16, 2025 | finanznachrichten.deAre You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great ChoiceJuly 16, 2025 | zacks.com5 Small Drug Stocks to Buy Amid Trump's New Tariff ThreatsJuly 16, 2025 | zacks.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and MetabolismJuly 16, 2025 | globenewswire.comZevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type CJuly 16, 2025 | quiverquant.comQZevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?July 16, 2025 | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystJuly 16, 2025 | marketbeat.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | finance.yahoo.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | zacks.comHere's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)July 15, 2025 | zacks.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by BrokeragesJuly 15, 2025 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from AnalystsJuly 15, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Raised to Strong-Buy at Wall Street ZenJuly 14, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Outlook for ZVRA EarningsJuly 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePFSCF, TYRA, DNA, and ZVRA Company DescriptionsGinkgo Bioworks NYSE:DNA$13.38 +2.06 (+18.21%) Closing price 03:58 PM EasternExtended Trading$13.64 +0.26 (+1.97%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.ProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Tyra Biosciences NASDAQ:TYRA$10.29 -0.32 (-3.02%) Closing price 04:00 PM EasternExtended Trading$10.28 -0.01 (-0.15%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.Zevra Therapeutics NASDAQ:ZVRA$11.58 -0.15 (-1.28%) Closing price 04:00 PM EasternExtended Trading$11.80 +0.22 (+1.93%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Block Levels Up: What S&P 500 Inclusion Means for Investors Steel Dynamics Stock Steady on Long-Term Prospects Amazon Stock Rally Hits New Highs: Buy Into Earnings? A Bullish Storm Is Brewing for High-Yield Verizon’s Share Price Forget the Hype—TSMC Is the AI Stock That Actually Delivers Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors Palantir Bulls and Bears Set for an August Showdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.